Status:

COMPLETED

Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL

Lead Sponsor:

Northwestern University

Collaborating Sponsors:

Robert H. Lurie Cancer Center

Conditions:

Non-Hodgkin's Lymphoma

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block canc...

Detailed Description

This is a multicenter, prospective study. * Induction therapy: Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15, and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of...

Eligibility Criteria

Inclusion

  • Histologically confirmed low-grade B-lymphocyte non-Hodgkins lymphoma
  • Life expectancy \> 12 months

Exclusion

  • No known history of HIV infection
  • No other active infection
  • No peripheral neuropathy ≥ grade 2 within the past 14 days
  • No uncontrolled hypertension
  • None of the following cardiac conditions:
  • Myocardial infarction within the past 6 months
  • No heart failure
  • Uncontrolled angina
  • Severe uncontrolled ventricular arrhythmias
  • Electrocardiographic evidence of acute ischemia
  • Active conduction system abnormalities
  • No serious medical or psychiatric illness that would preclude study compliance
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No prior therapy for non-Hodgkins lymphoma
  • No prior bortezomib or rituximab
  • At least 3 weeks since prior chemotherapy, radiation therapy, immunotherapy, systemic anticancer biologic therapy, or anticancer hormonal therapy
  • At least 2 weeks since prior investigational drugs
  • No other concurrent systemic cytotoxic chemotherapy or investigational agents + No leukemia

Key Trial Info

Start Date :

August 9 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 10 2014

Estimated Enrollment :

42 Patients enrolled

Trial Details

Trial ID

NCT00369707

Start Date

August 9 2006

End Date

October 10 2014

Last Update

September 6 2019

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

University of Miami Sylvester Comprehensive Cancer Center - Miami

Miami, Florida, United States, 33136

2

Hematology-Oncology Associates of Illinois

Chicago, Illinois, United States, 60611-2998

3

Northwestern University

Chicago, Illinois, United States, 60611

4

Fox Chase Cancer Center - Philadelphia

Philadelphia, Pennsylvania, United States, 19111-2497